Pratia S.A.

Wir sind Spezialist, kompetenter Partner und erfahrener Dienstleister in der Rekrutierung und Durchführung klinischer Prüfungen.

+ 49 40 460 763 90

info.germany@pratia.com

Hoheluftchaussee 18, 20253 Hamburg

Neueste News

Montag - Freitag 08:00 - 16:30

Samstag & Sonntag - geschlossen

+49 40 460 763 90

info.germany@pratia.com

Hoheluftchaussee 18

20253 Hamburg

Folge uns
Pratia S.A.  >  Allgemein   >  KFGN will operate under the Pratia site network branding from March 2023

KFGN will operate under the Pratia site network branding from March 2023

Click here for the German article.

Fresh breeze. Fresh colors. New spirit. As of March, the companies of the kfgn-Group appear under the branding of the European Site Network Pratia. With this step, the affiliation of the kfgn-Group to Pratia, which has existed since 2020, becomes even more visible for our partners. The message is: the high standard of 27 years of clinical research in Germany merges with the advantages and possibilities of a highly modern and high-tech European Site Network.

kfgn was founded in 1995 by Professor Hanns-Gerd Dammann. Since then, the network has carried out over 900 clinical studies, establishing itself as the clinical trials market leader in Germany. With its own six research sites in Hamburg, Schwerin, Hanover, Berlin, Dresden and Karlsruhe, kfgn is always near to its patients.

Pratia is a network of research sites with over 90 locations in six countries in Europe: Poland, Spain, Czech Republic, Bulgaria, Ukraine, Germany. With more than 1,500 clinical trials conducted since 2012, Pratia provides tech-savvy, adaptable solutions for innovative clinical trial treatments and sees itself as a platform that connects patients and investigators with the support of state-of-the-art technology. Pratia itself is part of the listed NEUCA Group.

NEUCA has held a strategic stake in kfgn via the NEUCA Capital Group since 2020 and has been the majority shareholder since summer 2022.

With the change in the majority interests, the cooperation between the kfgn-Group and Pratia will be intensified and new impulses will be set. This also includes changes in the management of kfgn. Since February 1st, 2023, the management and development of kfgn / Pratia Germany has been in the hands of the Site Network Director Ute Bertelsmann. She reports to Wojciech Szczepanik, who is the sole Managing Director of all kfgn companies and also Vice President of the International Site Network. Dr Ole Dammann resigned as Managing Director of kfgn as of January 31, 2023 and has been active at shareholder level since February 1, 2023.

For companies working with kfgn / Pratia Germany, the rebranding means:

  • The legal entities of all kfgn companies remain the same (no changes in contracts, submissions, etc.), neither the invoicing changes.
  • The business documents such as letters, hand-outs, presentations appear in the Pratia branding.
  • The kfgn staff will receive Pratia e-mail addresses (the existing kfgn addresses will still be active for incoming e-mails/log-ins)
  • Pratia logo will be visible at the sites.
  • kfgn / Pratia Germany is looking forward to your feedback.
  • Wojciech Szczepanik and Ute Bertelsmann are looking forward to hearing from you – the language is English for Wojciech Szczepanik and English/German for Ute Bertelsmann.
Pratia.de

Our Study Sites:

Our Project Team:

Inquiries: feasibility.germany@pratia.com
Applications: bewerbung@pratia.com
Data protection: datenschutz@pratia.com

Pratia S.A.

Wir sind Spezialist, kompetenter Partner und erfahrener Dienstleister in der Rekrutierung und Durchführung klinischer Prüfungen. Im Auftrag der forschenden Pharmaindustrie führen wir klinische Therapiestudien mit dem Schwerpunkt auf den Phasen Ib – IV durch und halten die dafür notwendigen Services bereit. Zu unseren Auftraggebern gehören pharmazeutische Firmen, Contract Research Organizations (CRO) und Firmen aus den Bereichen Biotechnologie und Medizinprodukte.

No Comments

Sorry, the comment form is closed at this time.